These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35853842)

  • 1. Particular challenges in the use of pulmonary vasodilating therapy for patients with pulmonary hypertension secondary to left heart disease. Letter regarding the article 'Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial'.
    Dandel M; Hetzer R
    Eur J Heart Fail; 2022 Oct; 24(10):1990. PubMed ID: 35853842
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial.
    Cooper TJ; Cleland JGF; Guazzi M; Pellicori P; Ben Gal T; Amir O; Al-Mohammad A; Clark AL; McConnachie A; Steine K; Dickstein K
    Eur J Heart Fail; 2022 Jul; 24(7):1239-1248. PubMed ID: 35596935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial.
    Hoendermis ES; Liu LC; Hummel YM; van der Meer P; de Boer RA; Berger RM; van Veldhuisen DJ; Voors AA
    Eur Heart J; 2015 Oct; 36(38):2565-73. PubMed ID: 26188003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary Vascular Distensibility Predicts Pulmonary Hypertension Severity, Exercise Capacity, and Survival in Heart Failure.
    Malhotra R; Dhakal BP; Eisman AS; Pappagianopoulos PP; Dress A; Weiner RB; Baggish AL; Semigran MJ; Lewis GD
    Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27301469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired Right Ventricular-Pulmonary Arterial Coupling and Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction: An Ancillary Analysis From the Phosphodiesterase-5 Inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) Trial.
    Hussain I; Mohammed SF; Forfia PR; Lewis GD; Borlaug BA; Gallup DS; Redfield MM
    Circ Heart Fail; 2016 Apr; 9(4):e002729. PubMed ID: 27072860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension.
    Liu LC; Hummel YM; van der Meer P; Berger RM; Damman K; van Veldhuisen DJ; Voors AA; Hoendermis ES
    Eur J Heart Fail; 2017 Jan; 19(1):116-125. PubMed ID: 27873388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study.
    Guazzi M; Vicenzi M; Arena R; Guazzi MD
    Circulation; 2011 Jul; 124(2):164-74. PubMed ID: 21709061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.
    Redfield MM; Chen HH; Borlaug BA; Semigran MJ; Lee KL; Lewis G; LeWinter MM; Rouleau JL; Bull DA; Mann DL; Deswal A; Stevenson LW; Givertz MM; Ofili EO; O'Connor CM; Felker GM; Goldsmith SR; Bart BA; McNulty SE; Ibarra JC; Lin G; Oh JK; Patel MR; Kim RJ; Tracy RP; Velazquez EJ; Anstrom KJ; Hernandez AF; Mascette AM; Braunwald E;
    JAMA; 2013 Mar; 309(12):1268-77. PubMed ID: 23478662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sildenafil in heart transplant candidates with pulmonary hypertension.
    de Groote P; El Asri C; Fertin M; Goéminne C; Vincentelli A; Robin E; Duva-Pentiah A; Lamblin N
    Arch Cardiovasc Dis; 2015; 108(6-7):375-84. PubMed ID: 25921840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exercise-induced pulmonary artery hypertension in a patient with compensated cardiac disease: hemodynamic and functional response to sildenafil therapy.
    Nikolaidis L; Memon N; O'Murchu B
    Tex Heart Inst J; 2015 Feb; 42(1):50-4. PubMed ID: 25873799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study.
    Belyavskiy E; Ovchinnikov A; Potekhina A; Ageev F; Edelmann F
    BMC Cardiovasc Disord; 2020 Sep; 20(1):408. PubMed ID: 32912157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Beraprost Sodium Combined with Sildenafil and Its Effects on Vascular Endothelial Function and Inflammation in Patients Experiencing Left Heart Failure Complicated with Pulmonary Arterial Hypertension.
    Sun D; Yang W; Wang Z; Gao B
    Med Sci Monit; 2021 Feb; 27():e928413. PubMed ID: 33531453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of ventilatory efficiency in heart failure: the role of right ventricular performance and pulmonary vascular tone.
    Lewis GD; Shah RV; Pappagianopolas PP; Systrom DM; Semigran MJ
    Circ Heart Fail; 2008 Nov; 1(4):227-33. PubMed ID: 19808296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of sildenafil for pulmonary hypertension due to left heart disease with HFrEF.
    Jiang R; Wang L; Zhu CT; Yuan P; Pudasaini B; Zhao QH; Gong SG; He J; Liu JM; Hu QH
    Hypertens Res; 2015 Dec; 38(12):829-39. PubMed ID: 26202179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial.
    Ghofrani HA; Reichenberger F; Kohstall MG; Mrosek EH; Seeger T; Olschewski H; Seeger W; Grimminger F
    Ann Intern Med; 2004 Aug; 141(3):169-77. PubMed ID: 15289213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β3 adrenergic agonist treatment in chronic pulmonary hypertension associated with heart failure (SPHERE-HF): a double blind, placebo-controlled, randomized clinical trial.
    García-Álvarez A; Blanco I; García-Lunar I; Jordà P; Rodriguez-Arias JJ; Fernández-Friera L; Zegri I; Nuche J; Gomez-Bueno M; Prat S; Pujadas S; Sole-Gonzalez E; Garcia-Cossio MD; Rivas M; Torrecilla E; Pereda D; Sanchez J; García-Pavía P; Segovia-Cubero J; Delgado JF; Mirabet S; Fuster V; Barberá JA; Ibañez B;
    Eur J Heart Fail; 2023 Mar; 25(3):373-385. PubMed ID: 36404400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.
    Lewis GD; Shah R; Shahzad K; Camuso JM; Pappagianopoulos PP; Hung J; Tawakol A; Gerszten RE; Systrom DM; Bloch KD; Semigran MJ
    Circulation; 2007 Oct; 116(14):1555-62. PubMed ID: 17785618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction.
    Borlaug BA; Lewis GD; McNulty SE; Semigran MJ; LeWinter M; Chen H; Lin G; Deswal A; Margulies KB; Redfield MM
    Circ Heart Fail; 2015 May; 8(3):533-41. PubMed ID: 25782985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial.
    Behr J; Nathan SD; Wuyts WA; Mogulkoc Bishop N; Bouros DE; Antoniou K; Guiot J; Kramer MR; Kirchgaessler KU; Bengus M; Gilberg F; Perjesi A; Harari S; Wells AU
    Lancet Respir Med; 2021 Jan; 9(1):85-95. PubMed ID: 32822614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design.
    Ghio S; Bonderman D; Felix SB; Ghofrani HA; Michelakis ED; Mitrovic V; Oudiz RJ; Frey R; Roessig L; Semigran MJ
    Eur J Heart Fail; 2012 Aug; 14(8):946-53. PubMed ID: 22719060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.